Haitong Leading Capital Management

Haitong Leading Capital Management is a Chinese private equity firm specializing in growth-stage investments across various industries. The firm manages the Shanghai Culture Industrial Investment Fund and is a wholly-owned subsidiary of Haitong Capital Investment Co., Ltd. Its business scope includes private equity investment fund management, investment consulting, and the establishment of investment funds.

The firm's investment strategy encompasses a wide range of sectors, including e-commerce, information technology, enterprise software, mobile applications, artificial intelligence, education technology, education, media and entertainment, and the service industry. Haitong Leading Capital Management focuses on multiple investment stages, such as early stage, growth, late stage, pre-IPO, and buyout opportunities.

With a registered capital of RMB 120 million, Haitong Leading Capital Management has made 15 investments, with an average round size of $32 million. The firm has led 5 investments and achieved 2 exits, demonstrating its active role in the private equity landscape. Its portfolio companies include Mabwell Biotech, a biotechnology firm specializing in innovative therapies.